Opus Genetics Announces Positive Clinical Trial Results for Gene Therapy and Phentolamine Ophthalmic Solution, Plans Key Data Presentations in October 2025
Reuters
Oct 02
<a href="https://laohu8.com/S/IRD">Opus Genetics</a> Announces Positive Clinical Trial Results for Gene Therapy and Phentolamine Ophthalmic Solution, Plans Key Data Presentations in October 2025
Opus Genetics Inc. has announced upcoming presentations of new clinical data from its pipeline at several medical and industry conferences in October 2025. The company will share three-month pediatric and 18-month adult clinical results from its Phase 1/2 trial of OPGx-LCA5, a gene therapy for Leber congenital amaurosis type 5 (LCA5), at both the Cell and Gene Meeting on the Mesa and Eyecelerator at the American Academy of Ophthalmology. In addition, pivotal Phase 3 data from the LYNX-2 trial evaluating Phentolamine Ophthalmic Solution 0.75% in post-keratorefractive patients with decreased mesopic visual acuity will be presented at the American Academy of Optometry Annual Meeting 2025. These results are scheduled to be presented during the respective conference sessions in October.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9538858-en) on October 02, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.